SCHEMBL1301049

SCHEMBL1301049

Cc1nc(-c2cccc(CBr)c2)no1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.70
DAO P14920 1/20 0.49
MET P08581 1/20 0.49
RAB9A P51151 4/20 0.49
NPC1 O15118 3/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
MAPK1 P28482 3/20 0.48
TDP1 Q9NUW8 3/20 0.48
HCRTR1 O43613 3/20 0.46
HCRTR2 O43614 3/20 0.46
SLC6A4 P31645 1/20 0.46
TSHR P16473 1/20 0.46
FFAR4 Q5NUL3 1/20 0.44
S1PR1 P21453 2/20 0.43
CHRNA7 P36544 1/20 0.43
MAPT P10636 2/20 0.42
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7411441 0.97 L3MBTL1 (0.71) L3MBTL1DAOMETRAB9ANPC1
SCHEMBL27536208 0.88 L3MBTL1 (0.66) L3MBTL1DAOMETRAB9ANPC1
SCHEMBL10066488 0.86 L3MBTL1 (0.72) L3MBTL1DAOMETRAB9ANPC1
SCHEMBL1300632 0.84 L3MBTL1 (0.70) L3MBTL1DAOMETRAB9ANPC1
SCHEMBL15265754 0.84 L3MBTL1 (0.70) L3MBTL1DAOMETRAB9ANPC1
Hydrochloric Acid SCHEMBL6565113 0.83 L3MBTL1 (0.68) L3MBTL1DAOMETRAB9ANPC1
SCHEMBL13130238 0.83 L3MBTL1 (1.00) L3MBTL1RAB9ANPC1SMN1; SMN2KMT2A
SCHEMBL1075209 0.82 L3MBTL1 (0.66) L3MBTL1DAOMETRAB9ANPC1
SCHEMBL12720575 0.82 L3MBTL1 (0.66) L3MBTL1DAOMETRAB9ANPC1
SCHEMBL13197072 0.82 L3MBTL1 (0.66) L3MBTL1DAOMETRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1149099-A2 IMIDAZO[4,5-C]-PYRIDINE-4-ON-DERIVATIVES MERCK PATENT GmbH (DE) 2001-10-31 EP claimed
WO-2000040583-A2 IMIDAZO[4,5-C]-PYRIDINE-4-ON-DERIVATIVES MERCK PATENT GMBH (DE) 2000-07-13 WO claimed
CN-119390668-A Compound with ketoxime ether structure and application thereof 复旦大学 2025-02-07 CN disclosed
US-10085986-B2 Pyrimidinone compounds and their use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-10-02 US disclosed
EP-2754660-B1 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-11-02 EP disclosed
EP-2754660-B1 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-11-02 EP disclosed
US-9376426-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-06-28 US disclosed
US-9376426-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-06-28 US disclosed
US-9284300-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-03-15 US disclosed
US-9284300-B2 Pyridazinone derivatives MERCK PATENT GMBH (DE) 2016-03-15 US disclosed
US-9221806-B2 2-(heterocyclylbenzyl)pyridazinone derivatives MERCK PATENT GMBH (DE) 2015-12-29 US disclosed
CN-1315942-A 2-oxo-j(2H)-quinoline derivatives MERCK PATENT GMBH (DE) 2001-10-03 CN disclosed
EP-1117664-A1 IMIDAZO[4,5-C-]-PYRIDINE-4-ONE DERIVATIVES WITH FACTOR XA INHIBITING EFFECT MERCK PATENT GmbH (DE) 2001-07-25 EP disclosed
EP-1107954-A1 2-OXO-$i(2H)-QUINOLINE DERIVATIVES MERCK PATENT GmbH (DE) 2001-06-20 EP disclosed
EP-1056743-A1 BENZAMINE DERIVATIVES MERCK PATENT GmbH (DE) 2000-12-06 EP disclosed
WO-2000051989-A1 PYRAZOLE-3-ON-DERIVATIVE AS FACTOR XA INHIBITORS MERCK PATENT GMBH (DE) 2000-09-08 WO disclosed
WO-2000020416-A1 IMIDAZO[4,5-C-]-PYRIDINE-4-ONE DERIVATIVES WITH FACTOR XA INHIBITING EFFECT MERCK PATENT GMBH (DE) 2000-04-13 WO disclosed
WO-2000012479-A1 2-OXO-2H-QUINOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2000-03-09 WO disclosed
WO-2000008005-A2 PIPERAZINONE DERIVATIVES MERCK PATENT GMBH (DE) 2000-02-17 WO disclosed
WO-1999031092-A1 BENZAMINE DERIVATIVES MERCK PATENT GMBH (DE) 1999-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10085986-B2 Pyrimidinone compounds and their use TPMT, DHFR, DPYD L3MBTL1 3615/4885DAO 934/4885MET 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.